Trellis Bioscience

Monoclonal antibody technology was the research breakthrough of the 1980’s. With the discovery by Milstein and Kohler in Cambridge, England, Hybritech became the first company dedicated to the production of monoclonal antibodies, commercializing the first diagnostic tests and leading to two subsequent companies that furthered monoclonal antibody development, GenProbe and IDEC. The use of monoclonal antibodies as therapeutics was limited because the human body developed an immune response to the early generation drugs; this problem was not circumvented until methods to generate or engineer human monoclonal antibodies were developed in the 1990’s. Protein based (antibody) therapeutics are now rapidly finding their way into the forefront of modern day medicine. The promise of this novel class of drugs is recognized widely within the pharmaceutical and biotechnology industries. Over 250 companies and research entities have monoclonal antibody therapeutics, either in clinical or pre-clinical development. Market penetration of monoclonal antibodies worldwide is estimated to reach $40 billion by 2018.

Contact Details: 2-B Corporate Drive South San Francisco California 94080 United States of America Tel: 650.616.1100 Fax: 650.589.4860 Email: info@trellisbio.com WWW: www.trellisbio.com/

Loading...

Recent Publications by Trellis Bioscience:
Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. Native human Abs represent attractive drug candidates; however, the low...	21st October, 2009	Trellis Bioscience, South San Francisco, CA 94080, USA.	J Immunol. 2009 Nov 15;183(10):6338-45. Epub 2009 Oct 19. DOI Direct Link
Antibody discovery via multiplexed single cell characterization. The secreted immunoglobulin footprint of single hybridoma cells,...	15th April, 2009	Trellis Bioscience, 2-B Corporate Dr., South San Francisco, CA 94080,	J Immunol Methods. 2009 Feb 28;341(1-2):135-45. Epub 2008 Dec 16. DOI Direct Link
Multiplexed Elispot assay. Micron scale latex beads are well established as highly biocompatible...	15th April, 2009	Trellis Bioscience, 2-B Corporate Dr., South San Francisco, CA 94080,	J Immunol Methods. 2009 Feb 28;341(1-2):127-34. Epub 2008 Dec 11. DOI Direct Link

Trellis Bioscience Patents:
US Patent No.	Title
7413868	Use of particulate labels in bioanalyte detection methods
7238490	Real time detection of intermolecular interaction
7060447	Protein localization assays for toxicity and antidotes thereto
6936427	Real time detection of intermolecular interaction
6867007	Binary or polynary targeting and uses thereof
→View more Trellis Bioscience patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 373 times since April 2007, the link to the organisation's website has been followed 71 times

Recent Search Terms used to find this page: Trellis Bioscience | trellis bioscience | .

Search for more companies in South San Francisco

Search for more companies in California

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Trellis Bioscience